Resistance and a lack of predictive biomarkers means that matching the best treatment options to patients is difficult. This study aims to characterise the extent of spatial and temporal ITH in advanced stage HGSOC at presentation and relapse.

**Methodology** Patients (n=49) having maximal effort upfront-debulking surgery for advanced HGSOC underwent a tumour mapping of their tumour dissemination patterns. Tumour biopsies were collected (range 4-15, median 9), when relapsed patients also had paired biopsies collected for genomic and phenotypic analysis. DNA was extracted from tumours (5 per patient, n=49 patients plus relapse samples) and Illumina Human OmniExpress genotyping performed. Allele-specific copy number (CN) was quantified using ASCAT. Genomic heterogeneity was quantified as the estimated number of CN aberration events distinct between each pair of tumour deposits. Clonal diversity within a patient’s deposits was calculated using the difference between within-patient and between-patient heterogeneity. Ki67 proliferation index was assessed from tumour sections collected prior to DNA extraction.

**Result(s)** Extensive genomic variations in patterns of evolution for different patients’ tumours was observed, including the relationship between matched primary tumours and relapsed disease. Widespread variations in CCNE1, MYC and PTEN CN were observed across multiple disseminated tumours in the same patients, and higher CCNE1 correlated with poor patient outcome (p=0.038). Extensive heterogeneity in Ki67 proliferation index was observed across the cohort, 77% of patients had tumour scores covering low, moderate and/or high Ki67 scoring categories.

**Conclusion** Broad ITH was observed at the genomic level across this cohort. Extensive CN variations in genes such as CCNE1, across multiple disseminated samples within patients, and widespread variations in proliferative index between multi-site tumours, indicates that a single tumour biopsy does not accurately depict disseminated HGSOC biology, and therefore should not be used for as a basis for prediction of patient prognosis or outcomes.

### 364 RADIOMICS AND MOLECULAR CLASSIFICATION IN ENDOMETRIAL CANCER (THE ROME STUDY): A STEP FORWARD TO A SIMPLIFIED PRECISION MEDICINE

**Introduction/Background** Molecular/genomic profiling is the most accurate method to assess prognosis of endometrial cancer patients. Similarly, the adoption of radiomics showed important results for screening, diagnosis and prognosis, across various radiological systems and oncologic specialties. Here, we aim to correlate radiomic features obtained from ultrasound images with the molecular/genomic profiling to identify new hallmarks for stratification of endometrial cancer patients into different classes of risk.

**Methodology** This prospective single-arm observational study Patients with newly diagnosed endometrial cancer will have ultrasonographic evaluation and radiomic analysis of the ultrasonographic images. Then patients will have surgery followed by molecular/genomic evaluation. We will correlate radiomic features with molecular/genomic profiling to classify prognosis.

**Result(s)** The central hypothesis is that combining radiomic features with molecular features might allow identifying various classes of risk for endometrial cancer, e.g. predicting unfavorable molecular/genomic profiling. We expect that the radiomic analysis of ultrasonographic images by means of radiomic classifier of risks will provide comparable results to molecular/genomic. (Trial Registration: GR-2019-12370566 Bando per la Ricerca Finalizzata 2019, Ministero della 24 Salute, Repubblica Italiana)
participating centers for local RAD51 scoring. For the scope of the RING trial, a predefined and uniform scoring methodology was applied. Scoring was performed blinded for genetic and clinical data. Specific features in the analysis of the co-IF, including the number of RAD51 foci per nucleus and the presence of RAD51 subclonality, i.e., distinct RAD51 positive and negative areas, were incorporated in the RAD51 scoring form. For non-normally distributed data, variability was analyzed using the median, 25th percentile (Q1) and 75th percentile (Q3).

**Result(s)** Median variability in RAD51 scores between observers in centrally stained slides was 21% (Q1: 15%; Q3: 24%) (figure 1). For the majority of cases (n = 10/12), a limited interobserver variability, defined as ≥ 3 observers with scores in a narrow range, was detected. In contrast, in cases where observers noted granular pannuclear RAD51 staining or RAD51 background, there was a substantial variability in scores (figure 1; case 6 and 8). Median variability in RAD51 scores between centrally and locally stained IF slides was 7.7% (Q1: 4.1%; Q3: 11.7%).

**Conclusion** This is the first cross-European interlaboratory assessment of the performance of RAD51/Geminin co-IF. We show that subtle local protocol differences do not impact final RAD51 scores. Furthermore, we elucidated features that may negatively impact RAD51 score accuracy.

---

**Efficacy Analysis of Niraparib Using Patient-Derived Xenograft of Rare Subtypes of Ovarian Cancer**

1H Asano*, 2K Hayashi, 3Y Matsuno, 4Y Hatanaka, 1H Watari. 1Hokkaido University, Department of Obstetrics and Gynecology, Sapporo, Japan; 2Hokkaido University Hospital, Center for Development of Advanced Diagnostics, Sapporo, Japan; 3Hokkaido University Hospital, Research Division of Genome Companion Diagnostics, Sapporo, Japan; 4Hokkaido University Hospital, Department of Surgical Pathology, Sapporo, Japan

10.1136/ijgc-2021-ESGO.593

**Introduction/Background** Niraparib, a PARP inhibitor, causes synthetic lethality in tumors with homologous recombination deficiency (HRD) and is now approved for ovarian cancer. However, the genetic alterations related to HRD rarely occur in ovarian cancers other than high-grade serous carcinoma or endometrioid carcinoma, thus the efficacy of niraparib for rare subtypes of ovarian cancer remains unclear. In this study, we investigated the efficacy of niraparib using Patient-Derived-Xenograft (PDX) models with rare subtypes of ovarian cancer and correlated between the efficacy and the expression levels of SLFN11 and ARID1A, a sensitizer of DNA-targeted therapies and a key component of the SWI/SNF complex, respectively.

**Methodology** We consecutively collected a total of 11 tissue specimens with a preoperative diagnosis of ovarian cancer which was surgically resected in our hospital. These tumors were directly transplanted subcutaneously into NOG mice and PDXs were established. The histologic characteristics were compared between parental tumors and PDX ones. Immunohistochemical (IHC) staining for ARID1A (D2A8U, Cell Signaling Technology) and SLFN11(D-2 sc-515071X, Santa Cruz) and genetic alterations of 160 cancer-related genes including ARID1A (Human Comprehensive Cancer Panel, Qiagen) were performed using the parental tumors. Response to carboplatin (CBDCA) and niraparib was analyzed using the PDX models.

**Result(s)** PDXs were established for each one case of carcinosarcoma (CS), adenocarcinoma (Adeno) with neuroendocrine carcinoma (NEC), and clear cell carcinoma (CCC). In histological comparison, PDX tumors generally mimicked the parental tumors. Loss of ARID1A in IHC was found in CCC and CS cases, and genetic alteration of ARID1A was also detected in the CCC case. Positive staining for SLFN11 was found in CS and Adeno with NEC, both of which had TP53 alterations. In the PDX of CS, both CBDCA and niraparib suppressed tumor growth in a dose-dependent manner. In the PDX of Adeno with NEC, CBDCA significantly suppressed tumor growth, while niraparib did not. The efficacy of CBDCA and niraparib is currently under consideration in the PDX of CCC.

**Conclusion** The combination of ARID1A and SLFN11 in IHC may be an efficacy biomarker for niraparib in rare subtypes of ovarian cancer. We plan to increase the sample size in the future.